These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 27575807)

  • 21. Analysis of endovascular therapy for femoropopliteal disease with the Supera stent.
    Montero-Baker M; Ziomek GJ; Leon L; Gonzales A; Dieter RS; Gadd CL; Pacanowski JP
    J Vasc Surg; 2016 Oct; 64(4):1002-8. PubMed ID: 27444365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endovascular treatment for symptomatic stent failures in long-segment chronic total occlusion of femoropopliteal arteries.
    Yang X; Lu X; Li W; Huang Y; Huang X; Lu M; Jiang M
    J Vasc Surg; 2014 Aug; 60(2):362-8. PubMed ID: 24680242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
    Ichihashi S; Shibata T; Fujimura N; Nagatomi S; Yamamoto H; Kyuragi R; Adachi A; Iwakoshi S; Bolstad F; Saeki K; Obayashi K; Kichikawa K
    J Endovasc Ther; 2019 Oct; 26(5):613-620. PubMed ID: 31257994
    [No Abstract]   [Full Text] [Related]  

  • 24. Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions.
    Dohi T; Iida O; Soga Y; Hirano K; Suzuki K; Takahara M; Uematsu M; Nanto S
    J Vasc Surg; 2014 Apr; 59(4):1009-1015.e1. PubMed ID: 24360237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease.
    Fujihara M; Utsunomiya M; Higashimori A; Yokoi Y; Nakamura M
    Heart Vessels; 2016 Feb; 31(2):152-7. PubMed ID: 25351136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular Response After FP-PES Versus Polymer-Free Paclitaxel-Eluting Stent Implantation in Femoropopliteal Artery Lesions: A Serial Intravascular Ultrasound Study.
    Tomoi Y; Kuramitsu S; Soga Y; Fujihara M; Iida O; Kawasaki D; Ando K
    JACC Cardiovasc Interv; 2020 Feb; 13(4):535-537. PubMed ID: 32081246
    [No Abstract]   [Full Text] [Related]  

  • 27. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
    Dake MD; Scheinert D; Tepe G; Tessarek J; Fanelli F; Bosiers M; Ruhlmann C; Kavteladze Z; Lottes AE; Ragheb AO; Zeller T;
    J Endovasc Ther; 2011 Oct; 18(5):613-23. PubMed ID: 21992630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
    Kichikawa K; Ichihashi S; Yokoi H; Ohki T; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
    Cardiovasc Intervent Radiol; 2019 Mar; 42(3):358-364. PubMed ID: 30411151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
    Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
    JACC Cardiovasc Interv; 2016 Feb; 9(3):271-277. PubMed ID: 26847118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
    Gouëffic Y; Kaladji A; Guyomarch B; Montagne C; Fairier D; Gestin S; Riche VP; Vent PA; Chaillou P; Costargent A; Patra P
    Trials; 2014 Oct; 15():423. PubMed ID: 25359394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
    Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
    JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular response to paclitaxel-eluting nitinol self-expanding stent in superficial femoral artery lesions: post-implantation angioscopic findings from the SHIMEJI trial (Suppression of vascular wall Healing after IMplantation of drug Eluting peripheral stent in Japanese patients with the Infra inguinal lesion: serial angioscopic observation).
    Tsukiyama Y; Shinke T; Ishihara T; Otake H; Terashita D; Kozuki A; Fukunaga M; Zen K; Horimatsu T; Fujii K; Shite J; Uematsu M; Takahara M; Iida O; Nanto S; Hirata KI
    Int J Cardiovasc Imaging; 2019 Oct; 35(10):1777-1784. PubMed ID: 31201589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of mortality following paclitaxel drug-coated stent angioplasty of femoropopliteal lesions in real world.
    Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Macharzina R; Nührenberg T; Cheung F; Neumann FJ; Zeller T
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1306-1314. PubMed ID: 32930497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early Post-Registry Experience With Drug-Eluting Stents in the Superficial Femoral Artery.
    Wooster M; Dansey K; Shames M
    Vasc Endovascular Surg; 2016 Feb; 50(2):80-3. PubMed ID: 26912397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
    Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
    J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
    J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries.
    Phillips JA; Falls A; Kolluri R; Whipp A; Collins C; Mohir-Sadaai S; Reid B; Patil N; Alston M; Troyan M; Ansel GM
    J Endovasc Ther; 2018 Jun; 25(3):295-301. PubMed ID: 29544372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty.
    Bisdas T; Beropoulis E; Argyriou A; Torsello G; Stavroulakis K
    JACC Cardiovasc Interv; 2018 May; 11(10):957-966. PubMed ID: 29798772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Propensity Score Analysis Comparing Clinical Outcomes of Drug-Eluting vs Bare Nitinol Stents in Femoropopliteal Lesions.
    Soga Y; Takahara M; Iida O; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Ando K
    J Endovasc Ther; 2016 Feb; 23(1):33-9. PubMed ID: 26763256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
    Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
    Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.